Acrivon announces dual WEE1/PKMYT1 inhibitor ACR-2316; plans IND by Q4 2024

Acrivon Therapeutics, Inc.

ACR-2316 is a novel dual WEE1/PKMYT1 inhibitor designed using Acrivon’s AP3 precision proteomics platform.
Preclinical studies show single-digit nM IC50 potency and potent single-agent anti-tumor activity in vitro and in vivo.
IND-enabling studies underway; IND submission targeted for Q4 2024 to initiate monotherapy development.
Updated corporate presentation confirms cash and marketable securities as of June 30, 2023, with cash runway into 2025.
Company prioritizes ACR-2316 based on preclinical profile for OncoSignature-based patient selection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.